Cellceutix Corp., of Beverly, Mass., said the briefing book with data collected during the phase I trial of Kevetrin for various advanced solid tumors has already been submitted to the FDA in advance of the meeting to discuss the planned phase II trial in advanced ovarian cancer. Kevetrin enhances activity of p53, a key tumor suppressor protein, in both wild-type and mutant p53-expressing tumors, the company said.